<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35316212</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1558-8238</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>132</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J Clin Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aerobic exercise elicits clinical adaptations in myotonic dystrophy type 1 patients independently of pathophysiological changes.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e156125</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI156125</ELocationID>
        <Abstract>
          <AbstractText>BackgroundMyotonic dystrophy type 1 (DM1) is a complex life-limiting neuromuscular disorder characterized by severe skeletal muscle atrophy, weakness, and cardiorespiratory defects. Exercised DM1 mice exhibit numerous physiological benefits that are underpinned by reduced CUG foci and improved alternative splicing. However, the efficacy of physical activity in patients is unknown.MethodsEleven genetically diagnosed DM1 patients were recruited to examine the extent to which 12 weeks of cycling can recuperate clinical and physiological metrics. Furthermore, we studied the underlying molecular mechanisms through which exercise elicits benefits in skeletal muscle of DM1 patients.RESULTSDM1 was associated with impaired muscle function, fitness, and lung capacity. Cycling evoked several clinical, physical, and metabolic advantages in DM1 patients. We highlight that exercise-induced molecular and cellular alterations in patients do not conform with previously published data in murine models and propose a significant role of mitochondrial function in DM1 pathology. Finally, we discovered a subset of small nucleolar RNAs (snoRNAs) that correlated to indicators of disease severity.ConclusionWith no available cures, our data support the efficacy of exercise as a primary intervention to partially mitigate the clinical progression of DM1. Additionally, we provide evidence for the involvement of snoRNAs and other noncoding RNAs in DM1 pathophysiology.Trial registrationThis trial was approved by the HiREB committee (no. 7901) and registered under ClinicalTrials.gov (NCT04187482).FundingNeil and Leanne Petroff. Canadian Institutes of Health Research Foundation (no. 143325).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mikhail</LastName>
            <ForeName>Andrew I</ForeName>
            <Initials>AI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagy</LastName>
            <ForeName>Peter L</ForeName>
            <Initials>PL</Initials>
            <AffiliationInfo>
              <Affiliation>Praxis Genomics LLC, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manta</LastName>
            <ForeName>Katherine</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, McMaster University Children's Hospital, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rouse</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Praxis Genomics LLC, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manta</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ng</LastName>
            <ForeName>Sean Y</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagy</LastName>
            <ForeName>Michael F</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Praxis Genomics LLC, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Praxis Genomics LLC, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Jian-Qiang</ForeName>
            <Initials>JQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Molecular Medicine/Neuropathology, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nederveen</LastName>
            <ForeName>Joshua P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, McMaster University Children's Hospital, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ljubicic</LastName>
            <ForeName>Vladimir</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tarnopolsky</LastName>
            <ForeName>Mark A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, McMaster University Children's Hospital, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Exerkine Corp., McMaster University Medical Center, Hamilton, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04187482</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Benefits of aerobic exercise in myotonic dystrophy type 1</RefSource>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009223" MajorTopicYN="Y">Myotonic Dystrophy</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010805" MajorTopicYN="Y">Physical Conditioning, Animal</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cell Biology</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        <Keyword MajorTopicYN="N">Muscle Biology</Keyword>
        <Keyword MajorTopicYN="N">Neuromuscular disease</Keyword>
        <Keyword MajorTopicYN="N">RNA processing</Keyword>
      </KeywordList>
      <CoiStatement><b>Conflict of interest:</b> MAT is the founder, CEO, and CSO of Exerkine Corp. PLN is the founder, owner, and CMO of Praxis Genomics.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>17</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35316212</ArticleId>
        <ArticleId IdType="pmc">PMC9106360</ArticleId>
        <ArticleId IdType="doi">10.1172/JCI156125</ArticleId>
        <ArticleId IdType="pii">156125</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chau A, Kalsotra A. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics. Dev Dyn. 2015;244(3):377–390. doi: 10.1002/dvdy.24240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dvdy.24240</ArticleId>
            <ArticleId IdType="pubmed">25504326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornton CA. Myotonic dystrophy. Neurol Clin. 2014;32(3):705–719. doi: 10.1016/j.ncl.2014.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ncl.2014.04.011</ArticleId>
            <ArticleId IdType="pmc">PMC4105852</ArticleId>
            <ArticleId IdType="pubmed">25037086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harley HG, et al.  Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature. 1992;355(6360):545–546. doi: 10.1038/355545a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/355545a0</ArticleId>
            <ArticleId IdType="pubmed">1346923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson NE, et al.  Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program. Neurology. 2021;96(7):e1045–e1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8055332</ArticleId>
            <ArticleId IdType="pubmed">33472919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taneja KL, et al.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol. 1995;128(6):995–1002. doi: 10.1083/jcb.128.6.995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.128.6.995</ArticleId>
            <ArticleId IdType="pmc">PMC2120416</ArticleId>
            <ArticleId IdType="pubmed">7896884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A, et al.  Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 2001;10(19):2165–2170. doi: 10.1093/hmg/10.19.2165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/10.19.2165</ArticleId>
            <ArticleId IdType="pubmed">11590133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JW, et al.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19(17):4439–4448. doi: 10.1093/emboj/19.17.4439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/19.17.4439</ArticleId>
            <ArticleId IdType="pmc">PMC302046</ArticleId>
            <ArticleId IdType="pubmed">10970838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philips A, et al.  Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 1998;280(5364):737–741. doi: 10.1126/science.280.5364.737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.280.5364.737</ArticleId>
            <ArticleId IdType="pubmed">9563950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuyumcu-Martinez NM, et al.  Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007;28(1):68–78. doi: 10.1016/j.molcel.2007.07.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2007.07.027</ArticleId>
            <ArticleId IdType="pmc">PMC2083558</ArticleId>
            <ArticleId IdType="pubmed">17936705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ET, et al.  Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015;25(6):858–871. doi: 10.1101/gr.184390.114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gr.184390.114</ArticleId>
            <ArticleId IdType="pmc">PMC4448682</ArticleId>
            <ArticleId IdType="pubmed">25883322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov. 2019;18(7):527–551. doi: 10.1038/s41573-019-0019-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-019-0019-2</ArticleId>
            <ArticleId IdType="pubmed">30867601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dial AG, et al.  The role of AMPK in neuromuscular biology and disease. Trends Endocrinol Metab. 2018;29(5):300–312. doi: 10.1016/j.tem.2018.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tem.2018.02.010</ArticleId>
            <ArticleId IdType="pubmed">29572064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manta A, et al.  Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice. J Physiol. 2019;597(5):1361–1381. doi: 10.1113/JP277123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP277123</ArticleId>
            <ArticleId IdType="pmc">PMC6395422</ArticleId>
            <ArticleId IdType="pubmed">30628727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravel-Chapuis A, et al.  Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles. Hum Mol Genet. 2018;27(19):3361–3376. doi: 10.1093/hmg/ddy245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddy245</ArticleId>
            <ArticleId IdType="pmc">PMC6140770</ArticleId>
            <ArticleId IdType="pubmed">29982462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bassez G, et al.  Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. Brain. 2018;141(10):2855–2865. doi: 10.1093/brain/awy231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awy231</ArticleId>
            <ArticleId IdType="pubmed">30169600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hood DA, et al.  Maintenance of skeletal muscle mitochondria in health, exercise, and aging. Annu Rev Physiol. 2019;81:19–41. doi: 10.1146/annurev-physiol-020518-114310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-physiol-020518-114310</ArticleId>
            <ArticleId IdType="pubmed">30216742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng SY, et al.  Mechanisms of exercise-induced survival motor neuron expression in the skeletal muscle of spinal muscular atrophy-like mice. J Physiol. 2019;587(18):4757–4778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6767691</ArticleId>
            <ArticleId IdType="pubmed">31361024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clawson LL, et al.  A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3–4):250–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29191052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brady LI, et al.  Impact of habitual exercise on the strength of individuals with myotonic dystrophy type 1. Am J Phys Med Rehabil. 2014;93(9):739–746. doi: 10.1097/PHM.0000000000000088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PHM.0000000000000088</ArticleId>
            <ArticleId IdType="pubmed">24743456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng SY, et al.  Exercise biology of neuromuscular disorders. Appl Physiol Nutr Metab. 2018;43(11):1194–1206. doi: 10.1139/apnm-2018-0229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/apnm-2018-0229</ArticleId>
            <ArticleId IdType="pubmed">29944848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roussel M, et al.  What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review. BMC Musculoskelet Disord. 2019;20(1):101.  doi: 10.1186/s12891-019-2458-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12891-019-2458-7</ArticleId>
            <ArticleId IdType="pmc">PMC6402179</ArticleId>
            <ArticleId IdType="pubmed">30836978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright NC, et al.  Aerobic walking in slowly progressive neuromuscular disease: effect of a 12-week program. Arch Phys Med Rehabil. 1996;77(1):64–69. doi: 10.1016/S0003-9993(96)90222-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0003-9993(96)90222-1</ArticleId>
            <ArticleId IdType="pubmed">8554477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kierkegaard M, et al.  Feasibility and effects of a physical exercise programme in adults with myotonic dystrophy type 1: a randomized controlled pilot study. J Rehabil Med. 2011;43(8):695–702. doi: 10.2340/16501977-0833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2340/16501977-0833</ArticleId>
            <ArticleId IdType="pubmed">21670942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ørngreen MC, et al.  Aerobic training in patients with myotonic dystrophy type 1. Ann Neurol. 2005;57(5):754–757. doi: 10.1002/ana.20460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20460</ArticleId>
            <ArticleId IdType="pubmed">15852373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thijs C, et al.  Age and causes of death in adult-onset myotonic dystrophy. Brain. 1998;121(pt8):1557–1563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9712016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelkonen M, et al.  Delaying decline in pulmonary function with physical activity: a 25-year follow-up. Am J Respir Crit Care Med. 2003;168(4):494–499. doi: 10.1164/rccm.200208-954OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200208-954OC</ArticleId>
            <ArticleId IdType="pubmed">12791579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angane EY, Navare AA. Effects of aerobic exercise on pulmonary function tests in healthy adults. Int J Res Med Sci. 2016;4(6):2059–2063.</Citation>
        </Reference>
        <Reference>
          <Citation>Huston TP, et al.  The athletic heart syndrome. N Engl J Med. 1985;313(1):24–32. doi: 10.1056/NEJM198507043130106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198507043130106</ArticleId>
            <ArticleId IdType="pubmed">3158817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zehender M, et al.  ECG variants and cardiac arrhythmias in athletes: clinical relevance and prognostic importance. Am Heart J. 1990;119(6):1378–1391. doi: 10.1016/S0002-8703(05)80189-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-8703(05)80189-9</ArticleId>
            <ArticleId IdType="pubmed">2191578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozaki H, et al.  Cycle training induces muscle hypertrophy and strength gain: strategies and mechanisms. Acta Physiol Hung. 2015;102(1):1–22. doi: 10.1556/APhysiol.102.2015.1.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1556/APhysiol.102.2015.1.1</ArticleId>
            <ArticleId IdType="pubmed">25804386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones K, et al.  GSK3β mediates muscle pathology in myotonic dystrophy. J Clin Invest. 2012;122(12):4461–4472. doi: 10.1172/JCI64081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI64081</ArticleId>
            <ArticleId IdType="pmc">PMC3533547</ArticleId>
            <ArticleId IdType="pubmed">23160194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 2014;157(1):77–94. doi: 10.1016/j.cell.2014.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.03.008</ArticleId>
            <ArticleId IdType="pubmed">24679528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pillon NJ, et al.  Transcriptomic profiling of skeletal muscle adaptations to exercise and inactivity. Nat Commun. 2020;11(1):470.  doi: 10.1038/s41467-019-13869-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-13869-w</ArticleId>
            <ArticleId IdType="pmc">PMC6981202</ArticleId>
            <ArticleId IdType="pubmed">31980607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121–135. doi: 10.1038/nrm.2017.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2017.95</ArticleId>
            <ArticleId IdType="pmc">PMC5780224</ArticleId>
            <ArticleId IdType="pubmed">28974774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker N, et al.  Linking mitochondrial dynamics, cristae remodeling and supercomplex formation: How mitochondrial structure can regulate bioenergetics. Mitochondrion. 2019;49:259–268. doi: 10.1016/j.mito.2019.06.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mito.2019.06.003</ArticleId>
            <ArticleId IdType="pubmed">31207408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landfeldt E, et al.  Change over time in ability to perform activities of daily living in myotonic dystrophy type 1. J Neurol. 2020;267(11):3235–3242. doi: 10.1007/s00415-020-09970-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-09970-6</ArticleId>
            <ArticleId IdType="pmc">PMC7578145</ArticleId>
            <ArticleId IdType="pubmed">32542526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascual-Gilabert M, et al.  Myotonic dystrophy type 1 drug development: A pipeline toward the market. Drug Discov Today. 2021;26(7):1765–1772. doi: 10.1016/j.drudis.2021.03.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drudis.2021.03.024</ArticleId>
            <ArticleId IdType="pmc">PMC8372527</ArticleId>
            <ArticleId IdType="pubmed">33798646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole C, et al.  Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial. Neurology. 2021;96(2):228–e240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7905778</ArticleId>
            <ArticleId IdType="pubmed">33046619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horrigan J, et al.  A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1) Pediatr Neurol. 2020;112:84–93. doi: 10.1016/j.pediatrneurol.2020.08.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.08.001</ArticleId>
            <ArticleId IdType="pubmed">32942085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawkins AM, et al.  Respiratory dysfunction in myotonic dystrophy type 1: A systematic review. Neuromuscul Disord. 2019;29(3):198–212. doi: 10.1016/j.nmd.2018.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2018.12.002</ArticleId>
            <ArticleId IdType="pubmed">30765255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roussel MP, et al.  Strength-training effectively alleviates skeletal muscle impairments in myotonic dystrophy type 1. Neuromuscul Disord. 2020;30(4):283–293. doi: 10.1016/j.nmd.2020.02.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2020.02.015</ArticleId>
            <ArticleId IdType="pubmed">32340814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malandish A, et al.  The effects of short-term moderate intensity aerobic exercise and long-term detraining on electrocardiogram indices and cardiac biomarkers in postmenopausal women. J Electrocardiol. 2020;60:15–22. doi: 10.1016/j.jelectrocard.2020.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jelectrocard.2020.03.004</ArticleId>
            <ArticleId IdType="pubmed">32208176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savkur RS, et al.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001;29(1):40–47. doi: 10.1038/ng704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng704</ArticleId>
            <ArticleId IdType="pubmed">11528389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martínez-Redondo V, et al.  Peroxisome proliferator-activated receptor γ coactivator-1 α isoforms selectively regulate multiple splicing events on target genes. J Biol Chem. 2016;291(29):15169–15184. doi: 10.1074/jbc.M115.705822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M115.705822</ArticleId>
            <ArticleId IdType="pmc">PMC4946932</ArticleId>
            <ArticleId IdType="pubmed">27231350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monsalve M, et al.  Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1α. Mol Cell. 2000;6(2):307–316. doi: 10.1016/S1097-2765(00)00031-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1097-2765(00)00031-9</ArticleId>
            <ArticleId IdType="pubmed">10983978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim N, et al.  AMPKα2 translocates into the nucleus and interacts with hnRNP H: implications in metformin-mediated glucose uptake. Cell Signal. 2014;26(9):1800–1806. doi: 10.1016/j.cellsig.2014.03.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2014.03.023</ArticleId>
            <ArticleId IdType="pubmed">24686086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH, et al.  HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res. 2005;33(12):3866–3874. doi: 10.1093/nar/gki698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gki698</ArticleId>
            <ArticleId IdType="pmc">PMC1176012</ArticleId>
            <ArticleId IdType="pubmed">16027111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardani R, et al.  Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2. PLoS One. 2013;8(12):e83777.  doi: 10.1371/journal.pone.0083777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0083777</ArticleId>
            <ArticleId IdType="pmc">PMC3869793</ArticleId>
            <ArticleId IdType="pubmed">24376746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isashiki Y, et al.  Mitochondrial abnormalities in extraocular muscles in myotonic dystrophy. Neuroopthalmology. 1989;9(2):115–122. doi: 10.3109/01658108909007466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01658108909007466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ono S, et al.  “Ragged-red” fibres in myotonic dystrophy. J Neurol Sci. 1986;74(2–3):247–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2426415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahashi K, et al.  Increased mitochondrial DNA deletions in the skeleal muscle of myotonic dystrophy. Gerontology. 1992;38(1–2):18–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1319380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gramegna LL, et al.  Mitochondrial dysfunction in myotonic dystrophy type 1. Neuromuscul Disord. 2018;28(2):144–149. doi: 10.1016/j.nmd.2017.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2017.10.007</ArticleId>
            <ArticleId IdType="pubmed">29289451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-puga M, et al.  Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin. Aging (Albany NY) 2020;12(7):6260–6275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7185118</ArticleId>
            <ArticleId IdType="pubmed">32310829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koutalianos D, et al.  miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1. Mol Ther Methods Clin Dev. 2021;23:169–183. doi: 10.1016/j.omtm.2021.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtm.2021.09.007</ArticleId>
            <ArticleId IdType="pmc">PMC8517008</ArticleId>
            <ArticleId IdType="pubmed">34703840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nair VD, et al.  Sedentary and trained older men have distinct circulating exosomal microRNA profiles at baseline and in response to acute exercise. Front Physiol. 2020;11:605.  doi: 10.3389/fphys.2020.00605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2020.00605</ArticleId>
            <ArticleId IdType="pmc">PMC7298138</ArticleId>
            <ArticleId IdType="pubmed">32587527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Håkansson KEJ, et al.  Circulating small non-coding RNAs as biomarkers for recovery after exhaustive or repetitive exercise. Front Physiol. 2018;9:1136.  doi: 10.3389/fphys.2018.01136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2018.01136</ArticleId>
            <ArticleId IdType="pmc">PMC6113669</ArticleId>
            <ArticleId IdType="pubmed">30246800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12890299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitney SL, et al.  Clinical measurement of sit-to-stand performance in people with balance disorders: validity of data for the Five-Times-Sit-to-Stand Test. Phys Ther. 2005;85(10):1034–1045. doi: 10.1093/ptj/85.10.1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ptj/85.10.1034</ArticleId>
            <ArticleId IdType="pubmed">16180952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Podsiadlo D, Richardson S. The timed ”up &amp; go”: a test of basic functional mobility for frail elderlv persons. J Am Geriatr Soc. 1991;39(2):142–148. doi: 10.1111/j.1532-5415.1991.tb01616.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1532-5415.1991.tb01616.x</ArticleId>
            <ArticleId IdType="pubmed">1991946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarnopolsky MA, et al.  Suction-modified Bergström muscle biopsy technique: experience with 13,500 procedures. Muscle Nerve. 2011;43(5):717–725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21462204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nilsson MI, et al.  A five-ingredient nutritional supplement and home-based resistance exercise improve lean mass and strength in free-living elderly. Nutrients. 2020;12(8):2391.  doi: 10.3390/nu12082391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu12082391</ArticleId>
            <ArticleId IdType="pmc">PMC7468764</ArticleId>
            <ArticleId IdType="pubmed">32785021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nederveen JP, et al.  Variability in skeletal muscle fibre characteristics during repeated muscle biopsy sampling in human vastus lateralis. Appl Physiol Nutr Metab. 2020;45(4):368–375. doi: 10.1139/apnm-2019-0263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/apnm-2019-0263</ArticleId>
            <ArticleId IdType="pubmed">32207991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimauro I, et al.  A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue. BMC Res Notes. 2012;5:513.  doi: 10.1186/1756-0500-5-513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-0500-5-513</ArticleId>
            <ArticleId IdType="pmc">PMC3508861</ArticleId>
            <ArticleId IdType="pubmed">22994964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D, et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907–915. doi: 10.1038/s41587-019-0201-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41587-019-0201-4</ArticleId>
            <ArticleId IdType="pmc">PMC7605509</ArticleId>
            <ArticleId IdType="pubmed">31375807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovaka S, et al.  Transcriptome assembly from long-read RNA-seq alignments with StringTie2. Genome Biol. 2019;20(1):278.  doi: 10.1186/s13059-019-1910-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-019-1910-1</ArticleId>
            <ArticleId IdType="pmc">PMC6912988</ArticleId>
            <ArticleId IdType="pubmed">31842956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders S, et al.  HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166–169. doi: 10.1093/bioinformatics/btu638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btu638</ArticleId>
            <ArticleId IdType="pmc">PMC4287950</ArticleId>
            <ArticleId IdType="pubmed">25260700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Love MI, et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):1–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4302049</ArticleId>
            <ArticleId IdType="pubmed">25516281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge SX, et al.  iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics. 2018;19(1):534.  doi: 10.1186/s12859-018-2486-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12859-018-2486-6</ArticleId>
            <ArticleId IdType="pmc">PMC6299935</ArticleId>
            <ArticleId IdType="pubmed">30567491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen S, et al.  rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci U S A. 2014;111(51):E5593–E5601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4280593</ArticleId>
            <ArticleId IdType="pubmed">25480548</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
